Want to see SE:ARCOMA full AI Analyst Report?

Arcoma AB (ARCOMA) Price & Analysis

0 Followers

ARCOMA Stock Chart & Stats

kr7.20

-kr0.40(-3.79%)

At close: Mar 06 4:00 PM EST

kr7.20

-kr0.40(-3.79%)

Day’s Range― - ―

52-Week Rangekr6.16 - kr10.05

Previous CloseN/A

Volume10.05K

Average Volume (3M)8.33K

Market Cap

kr108.74M

Enterprise Valuekr73.52M

Total Cash (Recent Filing)kr30.36M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)26.6

Beta0.04

Next Earnings

Feb 18, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.34

Shares Outstanding14,308,510

10 Day Avg. Volume7,401

30 Day Avg. Volume8,326

Financial Highlights & Ratios

PEG Ratio-0.36

Price to Book (P/B)1.41

Price to Sales (P/S)0.80

P/FCF Ratio8.02

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.55

Revenue Forecast (FY)kr135.00M

Bulls Say, Bears Say

Bulls Say

Minimal LeverageArcoma’s near-zero debt materially reduces refinancing and solvency risk while preserving flexibility to invest in products, software, and customer support. This conservative capital structure should help the company withstand operating volatility and fund opportunities without relying heavily on external financing.

Positive Cash GenerationPositive operating and free cash flow indicate that recent earnings are translating into cash rather than remaining purely accounting-based. This supports internal funding of operations and investment, improves resilience through the next several quarters, and gives management greater capital-allocation flexibility.

Recovery To Positive ProfitabilityThe return to positive operating profit and net income shows a meaningful recovery from the 2021–2022 loss period. Although current profitability is under pressure, an established profitable base can support reinvestment and provides a stronger platform for rebuilding margins than a loss-making position.

Bears Say

Severe Gross-margin CompressionThe sharp gross-margin deterioration is a major threat to durable earnings power because it leaves less revenue available to cover operating costs and fund development. Unless costs or product mix improve, continued compression could weaken profitability, cash generation, and competitive investment capacity.

Declining Revenue MomentumSofter revenue indicates that Arcoma is not currently expanding its top line, which can limit operating leverage and make margin recovery harder to achieve. Persistent contraction would reduce resources for product development and could weaken the company’s ability to build scale in digital radiography.

Volatile Cash-flow PerformanceAlthough current cash generation is positive, the history of negative cash flow and the recent step-down show that conversion is not consistently stable. Such variability can complicate budgeting and investment planning, particularly if weaker profitability or working-capital pressure persists.

ARCOMA FAQ

What was Arcoma AB’s price range in the past 12 months?

Arcoma AB lowest stock price was kr6.16 and its highest was kr10.05 in the past 12 months.

What is Arcoma AB’s market cap?

Arcoma AB’s market cap is kr108.74M.

When is Arcoma AB’s upcoming earnings report date?

Arcoma AB’s upcoming earnings report date is Feb 18, 2027 which is in 116 days.

How were Arcoma AB’s earnings last quarter?

Arcoma AB released its earnings results on Oct 22, 2026. The company reported kr0.165 earnings per share for the quarter.

Is Arcoma AB overvalued?

According to Wall Street analysts Arcoma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arcoma AB pay dividends?

Arcoma AB does not currently pay dividends.

What is Arcoma AB’s EPS estimate?

Arcoma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arcoma AB have?

Arcoma AB has 14,308,510 shares outstanding.

What happened to Arcoma AB’s price movement after its last earnings report?

Arcoma AB reported an EPS of kr0.165 in its last earnings report. Following the earnings report the stock price went up 2.828%.

Which hedge fund is a major shareholder of Arcoma AB?

Currently, no hedge funds are holding shares in SE:ARCOMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Arcoma AB

Arcoma AB is a global provider that designs, manufactures, and supplies cutting-edge radiology solutions. Their product line features advanced digital x-ray and radiography systems. These versatile systems are suitable for a wide array of radiographic applications and are utilized across various clinical environments, including general practice, musculoskeletal, thoracic, pediatric, and trauma/resuscitation units. The company distributes its products through a network of OEM partners. Arcoma AB was founded in 1990 and is headquartered in Växjö, Sweden.